$15.75
4.43% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US18507C1036
Symbol
CLPT
Sector

ClearPoint Neuro Stock price

$15.75
+3.64 30.06% 1M
+10.07 177.29% 6M
+8.96 131.96% YTD
+8.81 126.95% 1Y
+3.73 31.03% 3Y
+10.72 213.12% 5Y
+11.75 293.75% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.73 4.43%
ISIN
US18507C1036
Symbol
CLPT
Sector

Key metrics

Market capitalization $434.46m
Enterprise Value $416.58m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 13.69
P/S ratio (TTM) P/S ratio 14.28
P/B ratio (TTM) P/B ratio 14.98
Revenue growth (TTM) Revenue growth 36.34%
Revenue (TTM) Revenue $30.43m
EBIT (operating result TTM) EBIT $-18.85m
Free Cash Flow (TTM) Free Cash Flow $-8.91m
Cash position $21.57m
EPS (TTM) EPS $-0.69
P/E forward negative
P/S forward 13.65
EV/Sales forward 13.09
Short interest 2.74%
Show more

Is ClearPoint Neuro a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

ClearPoint Neuro Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a ClearPoint Neuro forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a ClearPoint Neuro forecast:

Buy
100%

Financial data from ClearPoint Neuro

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
30 30
36% 36%
100%
- Direct Costs 12 12
28% 28%
40%
18 18
42% 42%
60%
- Selling and Administrative Expenses 24 24
11% 11%
78%
- Research and Development Expense 12 12
8% 8%
38%
-17 -17
19% 19%
-56%
- Depreciation and Amortization 1.86 1.86
56% 56%
6%
EBIT (Operating Income) EBIT -19 -19
15% 15%
-62%
Net Profit -18 -18
17% 17%
-60%

In millions USD.

Don't miss a Thing! We will send you all news about ClearPoint Neuro directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ClearPoint Neuro Stock News

Neutral
Accesswire
about 2 months ago
Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United States SOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the U.S. Food and Drug Administration (FDA) has granted marketing authorizati...
Negative
Seeking Alpha
about 2 months ago
ClearPoint Neuro reported strong YoY growth in Q3, but the stock reacted negatively, probably due to its high valuation and weak sequential growth. Volatile performance should be expected in the near term due to the company's size and the immaturity of growth initiatives. ClearPoint's margins are improving, and cash burn is minimal, which should ease concerns about dilution.
Neutral
Seeking Alpha
about 2 months ago
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Joe Burnett - President & Chief Executive Officer Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Operator Greetings, and welcome to the ClearPoint Neuro, Inc. Third Quarter 2024 Financial Results Conference Call....
More ClearPoint Neuro News

Company Profile

Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Solana Beach, CA.

Head office United States
CEO Joseph Burnett
Employees 107
Founded 1998
Website www.clearpointneuro.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today